HONG KONG, Oct. 21, 2026 /PRNewswire/ -- On 20 October, the Sustainability Global Leaders Conference 2026 was held in Shanghai. The Conference, themed "Building a Resilient Future Together: Global Governance, Innovation-Driven Growth, and Industrial Upgrading", brought together more than 300 guests from around the world, including representatives of relevant United Nations agencies and various international organizations, Nobel Prize and Turing Award laureates, senior executives of leading domestic and international enterprises, and experts from leading think tanks.

Chen Qiyu, Co-CEO of Fosun International, was invited to attend the Conference and delivered a speech on the theme of "Value-Driven Globalization of Chinese Enterprises", titled "From Chinese Innovation to Global Value: Bringing the Benefits of Innovation to More Lives". Drawing on Fosun's experience, Chen Qiyu shared his views on how Chinese innovative drugs can reach global markets.

"Chinese innovative drugs are undergoing a historic transformation, evolving from participants in global innovation to contributors to it, and from serving the Chinese market to creating value globally," Chen Qiyu said.

Several figures bear this out: in 2025, the total value of out-licensing deals for Chinese innovative drugs was approximately USD136 billion; in the first half of 2026 alone, that figure exceeded USD100 billion. Meanwhile, clinical research assets originating from China accounted for about one-third of the global total, comparable to that of the United States.

"As Chinese innovative drug companies go global, what value should they create for the world?" Chen Qiyu said, "For Fosun, the fundamental purpose of innovation is to help more people live healthier lives and safeguard more lives."

Pushing the frontiers of science to meet patients' greatest needs

Pharmaceuticals and healthcare were among the first industries Fosun entered and have remained central to the Group's business ever since. In 1993, research related to PCR technology was awarded the Nobel Prize in Chemistry. Fosun, then in its early days, was already exploring the technology and developed a PCR-based diagnostic reagent for hepatitis B that same year. "That was Fosun's first encounter with the Nobel Prize," Chen Qiyu said.

For more than three decades of development, Fosun has kept pace with advances at the frontiers of science and technology. "In pharmaceuticals and healthcare, our innovation has always been driven by unmet clinical needs. We bring together scientific research, technology innovation and the capabilities needed to translate discoveries into medicines," Chen Qiyu said. "The innovations most worth investing in are those that can truly transform patients' lives."

Artesunate, known as a life-saving medicine for malaria patients across Africa, is a prime example. In the 1970s, Tu Youyou and her team discovered artemisinin. Building on that discovery, scientists and pharmaceutical researchers in Guilin, Guangxi, developed artesunate in 1977. In 2004, Fosun acquired Guilin Pharma, carrying this legacy of innovation forward.

For more than two decades thereafter, Fosun invested continuously in R&D, manufacturing process improvements, quality systems, international regulatory registrations and global market expansion. These efforts helped turn a discovery by Chinese scientists into a medicine that patients around the world could access.

In 2010, Artesun, an artesunate for injection, received World Health Organization (WHO) prequalification. In 2023, its second-generation product, Argesun, also received WHO prequalification. Argesun is particularly well suited to settings with limited healthcare resources. As of 30 June 2026, Fosun had cumulatively supplied more than 460 million vials of artesunate for injection worldwide, saving more than 92 million patients with severe malaria.

According to the World Malaria Report 2025, an estimated 14 million malaria deaths were averted worldwide between 2000 and 2024. Oral artemisinin-based medicines averted approximately 250,000 malaria deaths a year, while artesunate for injection averted around 150,000 malaria deaths a year.

"Scientific discovery brings new hope for patients. Sustained innovation and the ability to translate discoveries into medicines ensure that this hope reaches people around the world," Chen Qiyu said. "The value of Chinese innovation lies not only in developing world-class products, but also in making them accessible to more people worldwide."

The competitive edge of Chinese innovative drugs: affordability and reliability

Today, Chinese innovative drugs are becoming increasingly competitive. At the same time, a key question is emerging in the industry: what should underpin their competitive advantage globally? Chen Qiyu believes that two qualities are particularly important: affordability and reliability.

He cited the example of HANQUYOU, independently developed by Fosun's innovative biopharmaceutical platform, Henlius. HANQUYOU is a trastuzumab biosimilar for the treatment of HER2-positive breast cancer, gastric cancer and other conditions. The original drug had previously been very expensive. When HANQUYOU was launched in China in 2020, the estimated annual drug cost was around RMB130,000 for the original drug, compared with approximately RMB70,000 for HANQUYOU.

"This means more patients have the opportunity to receive high-quality biologic medicines and standardized treatment," Chen Qiyu said. "But our goal goes beyond affordable prices. We are equally committed to delivering quality that people can trust."

From the outset, Henlius has adhered to international standards in the development of its medicines. Rigorous quality comparability assessments and international multi-center clinical studies demonstrated a high degree of similarity between HANQUYOU and the innovator drug in quality, safety and efficacy.

After its approval in China, HANQUYOU received marketing approvals in the European Union (EU) and the U.S., becoming a China-developed monoclonal antibody biosimilar approved in three major markets. Today, it is available in more than 50 countries and regions worldwide.

"Chinese pharmaceutical companies are capable of developing medicines that are both affordable and able to meet the stringent requirements of leading global markets. Achieving both, however, remains a unique challenge for Chinese innovative drug companies," Chen Qiyu said.

He noted that innovative drug development requires significant investment, carries high risks and demands rigorous standards. Chinese innovative drug companies face the same R&D challenges and must meet the same international quality requirements as their global peers, while operating under tighter pricing constraints. As a result, simply replicating the traditional development model of multinational pharmaceutical companies is not enough. Instead, they must continually enhance innovation efficiency and lower R&D and manufacturing costs by leveraging technology platforms, advanced manufacturing, AI and lean operations to deliver high-quality innovation more effectively and efficiently.

Greater efficiency alone, however, will not sustain the development of world-class innovative drugs. Companies must also expand their global reach, ensuring that their innovations are widely adopted and generate appropriate returns.

"Chinese innovative drug companies must therefore build on their presence in China while remaining firmly committed to global expansion," Chen Qiyu said. "We must leverage the efficiency of Chinese innovation to compete globally, and the value generated in global markets to sustain further innovation. This is an important path for Chinese innovative drug companies as they go global."

From a single breakthrough to system-wide innovation: building a multinational innovative drug company rooted in China

"In the past, innovation often relied on a single technological breakthrough. Going forward, however, competitive advantage will increasingly depend on a company's ability to build a sustainable innovation system that consistently generates new drugs," Chen Qiyu said. Over the past three decades, Fosun Pharma has steadily built an open and globally integrated R&D network. Focusing on core therapeutic areas such as oncology, immunology and inflammation, it has established R&D platforms spanning small molecules, antibodies, antibody-drug conjugates (ADCs) and cell therapies, while expanding into cutting-edge therapeutic modalities such as radiopharmaceuticals.

In the first half of 2026, Fosun Pharma's total R&D investment rose 25.66% year-on-year to RMB3.247 billion. Of this total, RMB2.650 billion was invested in innovative drug R&D, representing a year-on-year increase of 48.38%. Revenue from innovative drugs grew 13.84% year-on-year to RMB4.911 billion, accounting for 33.35% of pharmaceutical business revenue.

Building on the success of HANQUYOU, Henlius has continued to achieve new breakthroughs. Its independently developed HANSIZHUANG became the world's first and only anti-PD-1 monoclonal antibody approved for perioperative treatment of gastric cancer. Henlius now has 10 products approved in over 60 countries and regions worldwide, benefitting more than 1.1 million patients. Its next-generation pipeline is also advancing rapidly. HLX43, an independently developed PD-L1 ADC with broad-spectrum anti-tumor activity and best-in-class potential, is being evaluated in more than ten clinical studies of HLX43 as monotherapy or in combination regimens, with more than 1,500 patients enrolled worldwide. Meanwhile, HLX22, a novel HER2-targeting monoclonal antibody, is being investigated for its therapeutic potential in gastric cancer, breast cancer and other indications.

As artificial intelligence (AI) advances at an unprecedented pace, it is emerging as a new driver of pharmaceutical innovation. Commenting on this trend, Chen Qiyu said, "AI is not merely a tool for improving efficiency; it has the potential to become a transformative force that reshapes the future of pharmaceutical innovation."

This year, Fosun Pharma completed the upgrade of its "PharmAID® Pharmaceutical Intelligence Platform V2.0", supporting AI-powered product development across the full lifecycle, from early-stage R&D and clinical validation to post-launch commercialization. To date, Fosun Pharma has rolled out more than 25 high-value AI projects, with more than 50 use cases simultaneously underway. These initiatives span multiple business functions, including pharmaceutical project evaluation, target prediction and molecule optimization. Two AI–assisted and structurally generated new molecules have entered the preclinical candidate (PCC) stage.

Looking ahead, Fosun Pharma has set a clear strategic goal: to become a multinational innovative drug company rooted in China, a "C-MNC". To achieve this goal, Chen Qiyu highlighted three concepts.

The first is "Chinese innovation", making China a major source of innovation by drawing on its combined strengths in scientific talent, clinical research and advanced manufacturing. This means pursuing original innovation and technological breakthroughs while building competitive advantages in products and costs through efficient R&D and large-scale manufacturing.

The second is "global collaboration", embracing open partnerships that connect China's capabilities with global resources. By drawing on the respective strengths of different countries and regions in R&D, regulatory registration and commercialization, Fosun aims to ensure its innovations deliver value in the markets that need them most.

The third is "accessibility and affordability", building on its established presence in China to serve emerging markets with a combined population of approximately 5.5 billion, it aims to bring more high-quality, affordable innovative drugs to Africa, Southeast Asia, Latin America and beyond.

"No matter how technology advances or the industry evolves, pharmaceutical companies must never lose sight of the fundamental purpose of innovation," Chen Qiyu said. In his view, sustainable growth is not simply about expanding a company's business, but about continuously creating value that benefits more patients and improves more lives around the world.

"Science determines how far innovation can go, but its true value is measured by the lives it improves," Chen Qiyu said. Looking ahead, Fosun will continue to drive growth through innovation, create greater value through global expansion, and fulfill its responsibilities by making healthcare more accessible and affordable. "Our goal is to bring more Chinese innovations to the world, enabling more families worldwide to enjoy healthier and happier lives through the power of scientific and technological progress."

香港2026年10月21日 /美通社/ -- 10月20日，2026可持續全球領導者大會在上海舉行。本屆大會以「共築韌性未來：全球治理、創新驅動與產業升級」為主題，匯聚來自全球的300餘位嘉賓，包括聯合國相關機構和多個國際組織的代表、諾貝爾獎與圖靈獎得主、國內外領軍企業高管及知名智庫專家。

復星國際聯席CEO陳啟宇應邀出席，圍繞「企業價值的全球化」發表題為《從中國創新到全球價值：讓創新潤澤更多生命》的演講，結合復星實踐，分享了對中國創新藥走向全球的路徑思考。

「中國創新藥正在迎來一次歷史性的跨越：從跟隨全球創新，走向貢獻全球創新；從中國市場的創新，走向全球價值的創造。」陳啟宇表示。

支撐這一判斷的是一組數據：2025年中國創新藥對外授權交易總金額約1,360億美元；僅2026年上半年，這一數字已突破1,000億美元。與此同時，來源中國的臨床研發資產約佔全球三分之一，與美國處於相近水平。

「中國創新藥企業走向世界，究竟要為全球創造什麼樣的價值？」陳啟宇表示，「對復星來說，創新有一個根本的使命，就是讓更多人獲得健康，讓更多生命得到守護。」

科學的前沿，就是生命最需要的地方

醫藥健康，是復星最早進入、長期堅持的核心業務領域。1993年，PCR技術相關研究獲得諾貝爾化學獎。那一年，創業剛剛起步的復星已把目光投向這項技術，並在同年研制出PCR乙肝診斷試劑。「這也是復星與諾貝爾獎的第一次『隔空握手』。」陳啟宇說。

在三十多年的發展歷程中，復星始終與世界科技創新的前沿站在一起。「在醫藥健康領域，我們始終堅持從未被滿足的臨床需求出發，推動科學研究、技術創新與產業化能力相結合。」陳啟宇表示，「最值得投入的創新，是那些能夠真正改變患者命運的創新。」

在非洲大陸被稱為瘧疾患者「救命藥」的青蒿琥酯就是典型的樣本。上世紀70年代，屠呦呦團隊發現青蒿素；1977年，廣西桂林的科研和製藥團隊在此基礎上研制出青蒿琥酯；2004年，復星收購桂林南藥，接過了這場創新接力的下一棒。

此後二十多年，復星持續投入技術研發、工藝升級、質量體系建設、國際註冊和全球市場拓展，把中國科學家的創新成果，真正轉化為全球患者能夠獲得的藥品。

2010年，注射用青蒿琥酯Artesun通過世界衛生組織預認證；2023年，第二代產品Argesun再次通過預認證，尤其適用於醫療資源不足的地區。截至2026年6月30日，復星已累計在全球供應超4.6億支注射用青蒿琥酯，救治超9,200萬名重症瘧疾患者。

《2025年世界瘧疾報告》顯示，2000至2024年，全球預計減少了1,400萬例瘧疾導致的死亡，其中，口服青蒿素類藥物每年可減少約25萬例瘧疾死亡，注射用青蒿琥酯每年可減少約15萬例瘧疾死亡。

「科學發現打開了生命的希望，而持續創新和產業化，讓這份希望跨越山海，真正抵達患者。」陳啟宇認為，中國創新的價值，不僅在於能做出世界一流的產品，更在於能讓全球更多人用上這些產品。

中國創新藥的核心競爭優勢：可負擔×可信賴

今天，中國創新藥已具備越來越強的競爭力，同時行業也在思考，中國創新藥究竟應該建立什麼樣的全球競爭優勢？陳啟宇認為，有兩點非常重要：可負擔和可信賴。他以復星生物創新藥平台復宏漢霖自主研發的漢曲優為例。漢曲優是用於治療HER2陽性乳腺癌、胃癌等疾病的曲妥珠單抗生物類似藥，它的原研藥曾經價格高昂。2020年，漢曲優在中國上市，按測算，使用原研藥一年的藥品費用約為人民幣13萬元，而使用漢曲優可以降低到約人民幣7萬元。

「這意味著，更多患者有機會用上高質量的生物藥，獲得規範治療。」陳啟宇同時強調，「但我們追求的，不只是可負擔的價格，更是可信賴的品質。」

從研發之初，復宏漢霖就按照國際標準推進產品開發，通過嚴格的質量比對和國際多中心臨床研究，證明產品與原研藥在質量、安全性和有效性方面的高度一致。

由此，繼在中國獲批上市後，漢曲優又先後獲得歐盟、美國批准上市，成為在中、歐、美三大市場均獲批的「中國籍」單抗生物類似藥。如今，漢曲優已經進入全球50多個國家和地區。

「中國藥企不僅能夠做出價格更可負擔的藥，也能夠做出獲得全球高標準市場認可的藥。這背後，意味著中國創新藥企業面臨著獨特的挑戰。」陳啟宇進一步闡釋，創新藥是一個高投入、高風險、高標準的行業，中國創新藥企業在面對同樣高的研發風險和國際質量標準時，還必須應對更加嚴格的價格約束。因此，簡單複製傳統跨國藥企的發展模式顯然不行，必須不斷提高創新效率，降低研發和生產成本，依靠技術平台、先進製造、人工智能和精益運營，以更高的效率，做更高水平的創新。

僅僅提高效率還不夠，要持續開發世界一流的創新藥，就必須在全球範圍內拓展市場空間，讓創新成果獲得更廣泛的應用和合理的價值回報。

「這就要求中國創新藥企業，在立足中國市場的同時，堅定走向全球。」陳啟宇說，「以中國創新效率，應對全球競爭；以全球市場價值，支撐持續創新。這將是中國創新藥企業走向世界的一條重要路徑。」

從單點突破到「體系創新」，打造源自中國的跨國創新藥企

「如果說過去的創新更多依靠單點技術突破，那麼未來的創新競爭，將越來越取決於企業能否構建持續產生創新成果的體系化能力。」陳啟宇介紹，過去三十多年，復星醫藥逐步構建起開放式、全球化的研發體系，圍繞腫瘤、免疫炎症等重點領域建立了涵蓋小分子、抗體、ADC、細胞治療等路徑的研發平台，並積極佈局核藥等前沿領域。

數據顯示，今年上半年，復星醫藥研發總投入人民幣32.47億元，同比增長25.66%，其中創新藥品相關研發投入人民幣26.50億元，同比增長48.38%；創新藥品收入人民幣49.11億元，同比增長13.84%，佔製藥業務收入比重升至33.35%。

繼漢曲優之後，復宏漢霖不斷取得突破，自主研發的H藥漢斯狀成為全球首個且唯一獲批胃癌圍術期適應症的抗PD-1單抗。目前，復宏漢霖已有10款產品在全球60餘個國家和地區獲批上市，惠及患者超110萬。下一代創新管線也在密集推進，自主研發的HLX43作為潛在同類最優的廣譜抗腫瘤PD-L1 ADC，目前已開展十餘項單藥或聯合臨床研究，累計全球入組患者超1,500例；針對HER2靶點的創新單抗HLX22正在探索胃癌、乳腺癌等領域的治療潛力。

如今，人工智能飛速發展，成為醫藥創新的新變量。對此，陳啟宇認為，「AI不僅是一種提高效率的工具，更有可能成為重構醫藥創新範式的重要力量。」

今年，復星醫藥完成了「PharmAID醫藥數智體系V2.0」升級，推動產品管線從早期研發到臨床確診再到上市後市場全生命週期AI賦能。目前，復星醫藥已有超25個高價值AI項目投產，50餘項場景同步推進，覆蓋醫藥項目評估、靶點預測、分子優化等各業務線；已有2個AI輔助生成及結構化的新分子進入臨床前候選化合物階段。

面向未來，復星醫藥提出了明確的戰略目標：打造源自中國的跨國創新藥企「C-MNC」。圍繞這一目標，陳啟宇給出了三個關鍵詞。

第一個關鍵詞是「中國創新」，即以中國為重要創新策源地，發揮科研人才、臨床研究、先進製造的綜合優勢，既追求源頭創新和技術突破，也通過高效研發、規模化生產形成產品與成本優勢。

第二個關鍵詞是「全球協同」，堅持開放合作，以中國能力嫁接全球資源，充分利用不同國家和地區的研發、註冊與商業化優勢，讓創新成果在最需要它們的市場實現價值。

第三個關鍵詞是「普惠可及」，立足中國，面向全球約55億人口的新興市場，將更多高質量、可負擔的創新藥帶到非洲、東南亞、拉美等地區。

「對於醫藥企業而言，無論技術如何進步、產業如何變革，都不能忘記創新最根本的出發點。」在陳啟宇看來，真正的可持續發展不僅是企業持續成長，更是企業創造的價值能持續惠及更多生命。

「創新的高度，由科技定義；創新的價值，由生命衡量。」陳啟宇表示，復星將堅持以創新驅動發展，以全球化拓展價值，以普惠醫療踐行責任，「讓更多源自中國的創新成果走向世界，讓全球更多家庭分享科技進步帶來的健康與幸福」。

• 64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive care.
• More than 10 studies have been selected to highlight the latest findings on HER2- and HER3-targeted antibody-drug conjugates (ADCs) in breast and lung cancers, advancing research on novel targets and exploring their clinical value across a range of applications.
• Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while developing new approaches for difficult-to-treat cancers such as pancreatic cancer. Hengrui puts patient needs at the center of its mission to deliver life-changing clinical value.

SHANGHAI, Oct. 21, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 will take place in Madrid, Spain, from October 23 to 27. Hengrui Pharma will present 64 research findings at the congress, including three studies accepted for Proffered Paper presentations, three for Rapid Oral presentations, 32 for Posters and 26 for e-Posters.

The ESMO Congress is a major global platform for innovative oncology drug development and scientific exchange. Hengrui Pharma has participated for 11 consecutive years since 2016, with a total of 119 research findings accepted between 2023 and 2025. This year, the number of accepted findings continues to grow, covering more than ten cancer areas, including esophageal, gastric, liver, biliary tract, pancreatic, rectal, breast, lung, cervical, prostate and nasopharyngeal cancers, as well as thymic epithelial tumors and sarcomas. The company will also host an exhibition booth for the second consecutive year, showcasing its latest progress in exploring novel targets, expanding the clinical value of its products, and developing its innovative pipeline.

Proffered Paper Presentations Highlight Novel Targets as Hengrui Pharma Advances ADC Innovation

Two independently developed ADCs from Hengrui Pharma, the HER2-targeted trastuzumab rezetecan (SHR-A1811) and the HER3-targeted ruzaltatug rezetecan (SHR-A2009), have both been selected for Proffered Paper presentations at the ESMO Congress. The studies address clinical treatment needs in breast and lung cancers, respectively. The data from these studies will be presented during the congress.

The Proffered Paper presentation on trastuzumab rezetecan will focus on progress from HORIZON-Breast06, a randomized phase 3 study in HER2-low advanced breast cancer, led by principal investigator Academician Binghe Xu of the Cancer Hospital at the Chinese Academy of Medical Sciences. One of the most representative products from Hengrui Pharma's ADC research and development platform, trastuzumab rezetecan is being developed for more than ten indications, including breast, lung, gastric, colorectal and cervical cancers. It is also among the innovative medicines with the highest number of breakthrough therapy designations in China. The study will further explore the therapeutic potential of trastuzumab rezetecan in this patient population and provide new evidence to support the expansion of its clinical applications.

The congress will also feature interim analyses from HERON-Lung01, a phase 3 trial comparing ruzaltatug rezetecan (SHR-A2009) with platinum-based chemotherapy in patients with EGFR-mutated advanced non-small-cell lung cancer that has progressed after EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. The trial is led by principal investigator Professor Yi-Long Wu of Guangdong Provincial People's Hospital. In July 2026, following positive results from HERON-Lung01, China's National Medical Products Administration (NMPA) accepted for review the marketing application for ruzaltatug rezetecan, intended to treat adults with EGFR-mutated locally advanced or metastatic non-squamous NSCLC whose disease has progressed following EGFR-TKI therapy. In addition, a Phase III clinical trial is currently underway to evaluate ruzaltatug rezetecan in combination with EGFR TKI as a first-line treatment for patients with EGFR-mutated locally advanced or metastatic NSCLC. Outside China, ruzaltatug rezetecan has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of patients with EGFR-mutated metastatic NSCLC whose disease has progressed following treatment with a third-generation EGFR-TKI and platinum-based chemotherapy.^[1] As development progresses from early exploration to larger-scale evaluation of efficacy, the latest findings on ruzaltatug rezetecan will provide new clinical evidence on the therapeutic potential of HER3-targeted ADCs in patients with non-small-cell lung cancer.

With HER2 and HER3 among its key targets, Hengrui Pharma has built an ADC development pipeline spanning multiple targets and continues to expand potential applications across cancer types and treatment settings. Its portfolio combines further development of established targets with exploration of emerging targets.

Advancing Commercialization and R&D Innovation to Expand Clinical Value

At this year's ESMO Congress, Hengrui Pharma will also present the latest research findings from its established products and innovative pipeline. Camrelizumab, a domestically developed PD-1 inhibitor with a leading number of approved indications and cancer types covered, will be featured in a Proffered Paper presentation about UNION, a phase 3 trial of neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer. Hengrui Pharma will also use the Rapid Oral session to present the latest findings on its phase 2 study into Nectin-4-targeted ADC SHR-A2102 in recurrent or metastatic cervical cancer, providing evidence to support further exploration of its clinical development potential in additional cancer types.

Alongside expanding existing treatment options, Hengrui Pharma is actively pursuing therapies for difficult-to-treat cancers such as pancreatic cancer. A combination regimen based on its independently developed KRAS G12D inhibitor HRS-4642 has been selected for a Rapid Oral presentation. This presentation will feature preliminary results from a phase 2 study of HRS-4642 plus chemotherapy, with or without adebrelimab, as perioperative therapy for KRAS G12D-mutant pancreatic cancer. HRS-4642 injection in combination with gemcitabine and nab-paclitaxel has been granted breakthrough therapy designation by the CDE of the NMPA for the first-line treatment of advanced or metastatic pancreatic cancer with a KRAS G12D mutation^[2]. The research may offer new treatment possibilities for patients with pancreatic cancer and new approaches to exploring targeted therapies for KRAS mutations.

From expanding the clinical value of established products to pursuing advances in its innovative pipeline and difficult-to-treat cancers, Hengrui Pharma continues to drive clinical value through R&D innovation, opening up more treatment possibilities for patients with cancer.

Expanding Development Pathways to Bring Chinese Innovation to the World

Following its first exhibition booth in 2025, Hengrui Pharma will again host a booth at this year's ESMO Congress, providing a platform for international scientific exchange on its innovative products and related research. Representatives from Hengrui Pharma's leading R&D and innovation teams will also attend the congress to engage with oncology experts and researchers from around the world and explore how pharmaceutical innovation can benefit more patients globally.

Jo Feng, President and COO of Hengrui Pharma, said: "This year marks the eleventh time we have participated in ESMO, with 64 research presentations - a new record for Hengrui. We look forward to sharing our latest advances in innovative drug development, presenting clinical evidence demonstrating meaningful benefits for patients, and bringing more Chinese innovation to benefit patients worldwide."

Hengrui Pharma will present additional research data and updates throughout this year's ESMO Congress, further demonstrating the exploration and development of innovative Chinese medicines in global oncology.

About Hengrui Pharma

Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

About Hengrui Oncology

Hengrui Oncology is one of Hengrui Pharma's core strategic business areas. Following decades of development, it has established a comprehensive portfolio spanning seven major disease areas, including gastrointestinal and breast cancers, as well as oncology supportive care. As of June 2026, 14 independently developed Class 1 innovative medicines, including AiRuiKa® (Camrelizumab for Injection), HengQu® (Herombopag Olamine Tablets) and AiWeiDa® (Trastuzumab Rezetecan for Injection), had been launched in China. Supported by its global R&D system and a range of international collaborations, Hengrui Oncology is accelerating its transition from innovation in China to innovation for the world, offering more precise, accessible and high-quality treatment options for patients with cancer.

For more information, please visit: www.hengrui.com

Appendix: Presentation Schedule for Key Hengrui Oncology Studies at ESMO Congress 2026 (link)
As of 19 October, 2026

Abstract number: LBA13

Study title: Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): a randomized, phase 3 study (HORIZON-Breast06)
Presenter: Ying Fan (Cancer Hospital, Chinese Academy of Medical Sciences)
Session name: Proffered paper 1: Breast cancer, early and advanced stage
Session time: October 23, 13:40 - 13:50 (local time)
Therapeutic area / subcategory: Breast cancer
Product: Trastuzumab rezetecan (SHR-A1811)
Venue: Alicante Auditorium, Hall 6

Abstract number: LBA72

Study title: Ruzaltatug rezetecan, a HER3-directed ADC, vs platinum-based chemotherapy (PBC) in EGFR-mutated advanced NSCLC progressing after EGFR-TKI: interim analyses (IA) from the phase 3 HERON-Lung01 trial
Presenter: Chongrui Xu (Guangdong Provincial People's Hospital)
Session name: Proffered paper 2: NSCLC, metastatic
Session time: October 26, 09:24 - 09:34 (local time)
Therapeutic area / subcategory: Lung cancer / Non-small-cell lung cancer
Product: Ruzaltatug rezetecan (SHR-A2009)
Venue: Alicante Auditorium, Hall 6

Abstract number: LBA85

Study title: HRS-4642 Plus Chemotherapy ± Adebrelimab as Perioperative Therapy in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Results of a Phase 2 Study
Presenter: Chenlei Wen (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)
Session name: Rapid oral 2: Gastrointestinal tumour, upper digestive
Session time: October 26, 14:45 - 14:50 (local time)
Therapeutic area / subcategory: Gastrointestinal cancers / Pancreatic cancer
Products: HRS-4642 ± adebrelimab
Venue: Barcelona Auditorium, Hall 9

Abstract number: 3530O

Study title: Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial
Presenter: Zhen Yu Lin (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology)
Session name: Proffered paper: Gastrointestinal tumours, lower digestive
Session time: October 25, 11:10 - 11:20 (local time)
Therapeutic area / subcategory: Gastrointestinal cancers / Rectal cancer
Product: Camrelizumab
Venue: Almeria Auditorium - Hall 9

Abstract number: 1244RO

Study title: SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study
Presenter: Jieping Chen (Sun Yat-sen University Cancer Center)
Session name: Rapid oral 1: Gynaecological cancers
Session time: October 23, 16:20 - 16:25 (local time)
Therapeutic area / subcategory: Gynecological cancers / Cervical cancer
Product: SHR-A2102
Venue: Burgos Auditorium - Hall 3

Abstract number: 4155RO

Study title: Rivoceranib in patients with pretreated metastatic thymic epithelial tumors: phase II multi-center KCSG LU23-09 (THRIVE) trial
Presenter: Sehhoon Park (Seoul, Republic of Korea)
Session name: Rapid oral: Non-metastatic NSCLC and other thoracic malignancies
Session time: October 26, 11:02 - 11:07 (local time)
Therapeutic area / subcategory: Other / Thymic epithelial tumors
Product: Apatinib
Venue: Burgos Auditorium - Hall 3

中國蘇州2026年10月21日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）今日宣佈，公司原創1類新藥Bcl-2抑制劑利生妥®（通用名：利沙托克拉，研發代號：APG-2575）獲國家藥品監督管理局（NMPA）藥品審評中心（CDE）納入「突破性治療品種」名單，用於聯合阿可替尼治療成人初治慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。

突破性治療品種通常被授予用於防治嚴重危及生命或者嚴重影響生存質量的疾病、且尚無有效防治手段或者與現有治療手段相比有足夠證據表明具有明顯臨床優勢的創新藥或者改良型新藥等。對於被納入突破性治療品種的藥物，CDE將優先配置資源進行溝通交流，加強指導並促進藥物研發進程；申請人經評估符合相關條件的，也可以在申請產品上市許可時提出附條件批准申請和優先審評審批申請。突破性治療品種的審評政策將加快具有重大臨床價值、臨床急需的創新藥或者改良型新藥的開發與上市。

CLL/SLL是一種成熟B淋巴細胞克隆增殖性腫瘤，多發於老年患者，全球每年新增病例超過10萬例¹。近年來在中國的發病率呈上升趨勢，且部分患者具有發病年齡低、腫瘤侵襲性高等特點²。

在CLL/SLL治療領域，免疫化療和BTK抑制劑已作為一線治療選擇並獲得了較好的反應率和生存結局，但仍存在一定局限性。對於部分患者，特別是一些伴有del(17p)/TP53突變、複雜核型、IGHV無突變等高危因素的患者，免疫化療療效有限，即便是BTK抑制劑單藥治療，也面臨緩解深度不足、長期安全性不夠理想的問題，且該方案要求持續治療，一旦治療失敗，患者後續可選擇的再治療手段十分有限，且效果不佳。因此，臨床急需開發固定療程聯合治療策略，在提高療效及緩解深度的同時減少不良反應發生。目前國內存在較大的、未被滿足的臨床需求。

利生妥^®是亞盛醫藥自主研發的新型口服Bcl-2選擇性抑制劑，於2025年7月在中國獲批上市，用於既往經過至少一種含BTK抑制劑在內的系統治療的成人CLL/SLL患者。利生妥^®為中國首個獲批上市的國產原創Bcl-2抑制劑，也是全球首個上市的單藥治療BTK抑制劑經治CLL/SLL的Bcl-2抑制劑。目前，亞盛醫藥正在開展利生妥^®的四項全球註冊III期臨床研究。其中一項全球註冊III期臨床研究（GLORA-2），旨在探索利生妥^®聯合阿可替尼一線治療CLL/SLL的臨床潛力。

亞盛醫藥首席醫學官翟一帆博士表示：「此次利生妥^®納入突破性治療品種，是對該聯合方案在初治CLL/SLL領域臨床潛力的肯定，也印證了這一臨床需求的迫切性。我們將繼續努力，加速推進利生妥^®相關適應症的全球臨床開發，早日惠及更多患者。」

參考資料：

1. Yao, Y., Lin, X., Li, F., et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022 Jan 11;21(1):4. DOI: 10.1186/s12938-021-00973-6
2. 劉澎. 復旦大學附屬中山醫院慢性淋巴細胞白血病/小淋巴細胞淋巴瘤診療規範（2018）[J].中國臨床醫學, 2018, 25(1): 157-160. DOI: 10.12015/j. issn.1008-6358.2018.20180

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球範圍內進行知識產權佈局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物製藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關係。如需瞭解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2026年4月29日提交的20-F表格中截止2025年12月31日的年度報告中的「風險因素」和「關於前瞻性聲明的警示聲明」章節，2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

BEIJING, Oct. 20, 2026 /PRNewswire/ -- CATL today unveiled the innovative dual-electric range extension battery and the latest generation of heavy-duty battery-swapping solution to accelerate the electrification of road freight transportation.

Competition in electric heavy-duty trucking is moving beyond technical specifications toward full-lifecycle value. While battery swapping has made energy replenishment faster and more predictable, concerns about battery utilization, operating costs and residual vehicle value continue to affect fleet economics.

To address these challenges, CATL combines its dual-electric range extension battery with QIJI's strategy of standardization, new infrastructure and a full commercial ecosystem, bringing battery swapping and industry-wide collaboration together to accelerate heavy-duty truck electrification.

A Dual-Electric Approach to Range Extension

CATL's dual-electric range extension battery combines two independent yet complementary battery systems.

The main battery uses QIJI's standardized chassis-mounted swappable battery to maximize efficiency. A behind-the-cab range-extension power system, currently equipped with a 77kWh battery capable of 3C charging, provides backup power. Together, the systems maintain uninterrupted power delivery and provide redundancy for demanding operating conditions.

• Dual-System Power Redundancy
  
  In conventional battery-swapping trucks, drivers often return for a swap with unused capacity because they are reluctant to run the battery low. Backup power from the range-extension battery increases the main battery's depth of discharge (DOD) from approximately 70% to over 95%, allowing it to be returned at less than 5% state of charge (SOC). At this threshold, CATL's seamless switching technology transfers power delivery to the range-extension battery within milliseconds, maintaining a continuous and stable power supply.

• "1+X" Architecture and Independent Upgrades
  
  The system uses a "1+X" architecture. One standardized main battery maintains compatibility with the QIJI battery-swapping network, while the range-extension battery can be customized for specific conditions with options including ultra-high energy density, low-temperature resistance for cold climates, or ultra-high power.
  
  The two battery systems can be developed and upgraded independently to meet their respective technical and operational requirements.

• Flexible Leasing and Battery Asset Management
  
  The independently owned on-board range-extension battery stays with the vehicle as an asset throughout its service life, reducing reliance on immediate access to a swapping station. The main battery can be leased according to seasonal freight demand, helping fleets reduce rental costs during quieter periods and manage battery assets more flexibly.
  
  This architecture combines the benefits of standardization with flexible vehicle configurations, making electric heavy-duty trucks more practical and economically viable across a wider range of applications.

QIJI Builds a Shared Battery Swapping Ecosystem

QIJI complements these improvements with a three-pillar strategy of standardization, new infrastructure and a full commercial ecosystem. It seeks to speed heavy-duty truck electrification with a value-chain ecosystem co-created by all stakeholders, where benefits are shared collectively.

• Standardization Supports Wider Adoption
  
  To accommodate a wider range of truck models and operating conditions, QIJI has introduced the 260# (432 kWh) and 300# (513 kWh) standardized battery-swapping blocks alongside the existing 75# block.
  
  The system enables battery swaps in just five minutes, with a 99.99% first-time success rate, helping fleets minimize downtime and maintain operational efficiency.
  
  QIJI has also pioneered a battery-as-a-service (BaaS) model in which customers pay for the net energy charged rather than the energy discharged. This allows customers to retain the value of energy recovered through regenerative braking, reducing per-kWh battery rental costs for users on basic plans by up to 20%. Flexible battery leasing options allow customers to tailor rental periods to their needs, from second-hand vehicle transitions to seasonal demand. This will minimize idle costs and offer more flexible options for off-season downtime, further helping fleets manage operating costs.

• New Infrastructure Improves Resource Efficiency
  
  QIJI aims to make better use of four critical resources in long-haul freight: time, land, payload capacity and grid electricity. Rapid battery swapping reduces waiting times, while efficient station layouts serve more vehicles within the same footprint. Battery capacity is matched to transport needs, and centralized, coordinated charging makes better use of grid electricity. These measures aim to improve both resource efficiency and operational returns.
  
  CATL plans to deploy 900 battery-swapping stations by the end of 2026 and 2,000 by 2027, with a long-term target of 10,000 stations nationwide in collaboration with its partners.
  
  By connecting major freight corridors through a coordinated swapping network, QIJI aims to improve the efficiency and commercial viability of electric heavy-duty trucking.

• A Commercial Ecosystem Supports the Full Vehicle Lifecycle
  
  QIJI connects truck manufacturers, financial institutions, insurers, channel partners and aftermarket service providers across the vehicle lifecycle, from purchase and operation to maintenance and resale, working together to build a comprehensive ecosystem of integrated products and services.
  
  QIJI has introduced two partnership models: Battery Asset Service Partners and Energy Replenishment Service Partners. These models allow partners to participate in battery asset services and energy replenishment, extending their role beyond one-off vehicle sales to ongoing operations.
  
  Through this integrated ecosystem, QIJI aims to turn the costs of the low-carbon transition into new growth opportunities, enabling stakeholders across the value chain to share the benefits of the new-energy era.

"The combination of the dual-electric range extension battery and QIJI battery swapping offers the best solution for electrifying heavy-duty trucks," said Jesse Yang, CEO of QIJI Energy.

New Batteries and Industry Partnerships

The initiative has also gained commercial traction, with agreements signed for 13,000 units at the event.

Aside from the dual-electric solution, CATL also introduced a new lineup of heavy-duty truck batteries tailored to different vehicle configurations and operating requirements at the event. The lineup includes rear-mounted ultra-light and ultra-thin batteries for weight- and space-sensitive applications, as well as chassis-mounted solutions for short-haul and long-haul operations.

SHANGHAI, Oct. 20, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received Frost & Sullivan's 2026 Global Company of the Year Recognition in the CRDMO industry for the tenth consecutive year.

Frost & Sullivan highlighted WuXi AppTec's integrated CRDMO model, which enables the company to support customers across the full drug development lifecycle, from early discovery through commercial manufacturing. The firm noted WuXi AppTec's global capacity, operational consistency, and ability to adapt to increasingly complex modalities as key differentiators.

"WuXi AppTec distinguishes itself through its strong focus on evolving customer needs," said Unmesh Lal, Vice President of Healthcare and Life Sciences at Frost & Sullivan. "Its commitment to customer success reinforces its position as a trusted partner to biopharmaceutical innovators worldwide."

"We are honored that Frost & Sullivan has once again recognized what our teams deliver every day for customers," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "As a dedicated enabler of the pharmaceutical industry, we remain committed to our CRDMO strategy and to helping customers around the world bring life-changing therapies to patients faster."

Frost & Sullivan's Company of the Year Recognition is its top honor, recognizing companies that exemplify visionary innovation, market-leading performance, and unmatched customer care.

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

BEIJING, Oct. 19, 2026 /PRNewswire/ -- Kingsoft Cloud Holdings Limited ("Kingsoft Cloud" or the "Company") (NASDAQ: KC and HKEX: 3896), a leading cloud service provider in China, is pleased to announce that its Environmental, Social and Governance (ESG) rating by Morgan Stanley Capital International ("MSCI") recently has been upgraded from "AA" to "AAA" (the highest tier), marking its third rating upgrade from 2022 to 2026. This achievement highlights Kingsoft Cloud's continuous commitment to excellence in ESG practices.

Kingsoft Cloud introduced its "CLOUD" sustainability strategy in its 2025 ESG Report, encompassing Corporate Governance, Labor Cultivating, Operational Excellence, Unified Eco-Creation and Digital Innovation. Under this framework, the Company continues to enhance its practices across key areas including technological innovation, privacy and data security, customer service, talent development, business ethics and compliance, while promoting the sustainable development of its cloud business in the AI era.

MSCI ESG Ratings are designed to measure a company's resilience to financially relevant, industry-specific sustainability risks and opportunities relative to its peers. Ratings range from AAA to CCC, with AAA being the highest level. The ratings serve as an essential benchmark for institutional investors in risk management and capital allocation.

Looking ahead, Kingsoft Cloud will focus on delivering the strategy of "High-Quality Sustainable Development", and continue to integrate sustainability into its technological innovation and business operations, strengthen its ESG governance, and create long-term value for customers, employees, shareholders and the broader community.

About Kingsoft Cloud Holdings Limited

Kingsoft Cloud Holdings Limited (NASDAQ: KC and HKEX: 3896) is a leading cloud service provider in China. Kingsoft Cloud has built a comprehensive and reliable cloud platform consisting of extensive cloud infrastructure, cutting-edge cloud products and well-architected industry specific solutions across public cloud and enterprise cloud.

For more information, please visit: http://ir.ksyun.com.

For more information, please contact:

Kingsoft Cloud Holdings Limited
Email: [email protected]

中國蘇州2026年10月19日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）今日宣佈，公司與蘇州大學及蘇州大學附屬第一醫院於日前完成戰略合作簽約儀式。本次合作是創新藥龍頭企業與高校、醫院的強強攜手，也是校院企三方貫徹剛剛召開的全國衛生與健康大會精神、助力健康中國建設的具體行動。三方將聚焦血液腫瘤，依託各自優勢開展深度合作，助力創新藥產業高質量發展，推動中國原創新藥走向世界惠及更多患者。

蘇州大學校長張橋，蘇州醫學院黨委書記王欣，科學技術研究院院長李耀文，產業技術研究院院長田天，校長辦公室副主任（主持工作）何德超，附屬第一醫院黨委副書記王海芳，蘇州醫學院藥學院院長、蘇州創新藥研究院執行院長鍾志遠，血液系統疾病國家臨床醫學研究中心綜合辦主任王熒，以及亞盛醫藥董事長兼首席執行官楊大俊、大中華市場運營總經理祝剛、運營高級副總經理張玉斌等出席簽約儀式。

本次活動由王欣書記主持，張橋校長、王熒主任、王海芳副書記和楊大俊博士分別致辭。王海芳副書記與祝剛共同簽署戰略合作協議，鍾志遠院長與張玉斌共同簽署科研專項合作協議。

張橋校長表示：「首先，感謝亞盛醫藥長期以來對蘇州大學及蘇大附一院的信任與厚愛，特別是對蘇州創新藥研究院的大力支持，在楊大俊博士等科創企業家的參與助力下，創新藥研究院聯合培養博士的新模式得以順利開展。第二，感恩蘇大附一院血液科團隊打下的優秀基礎，這也是我們服務蘇州生物醫藥產業的核心力量。蘇州大學將持續整合校內資源、深化產教融合，全力以赴支持亞盛醫藥與蘇大附一院、蘇州大學的長期合作，拿出最大誠意與亞盛共同成長，讓臨床一線的真問題轉化為科學問題，最終變成老百姓用得起的好藥。」 

王熒主任表示：「蘇大附一院血液科是醫院傳統的優勢科室，經過數十年努力在血液腫瘤治療領域形成了領先的臨床科研優勢，於2019年獲評血液系統疾病國家臨床醫學研究中心。自2020年與亞盛醫藥共建血液系統疾病國家臨床醫學研究中心亞盛研究院以來，我們見證了一款候選藥物從早期研究到真正上市、填補中國臨床空白的全過程。這項合作讓我們深刻體會到，臨床端深度參與新藥研發鏈條、在研究設計階段納入患者真實需求，能實質性縮短創新藥從實驗室到臨床的距離。此次合作上升至醫院與大學層面的戰略協同，既是對既往成果的肯定，更是面向未來的深度擴展，我們將推動臨床資源、研究平台與企業創新研發能力深度融合，讓更多創新藥更快惠及患者。」

王海芳副書記表示：「蘇大附一院與亞盛醫藥的合作基礎十分深厚。2020年雙方共建血液系統疾病國家臨床醫學研究中心亞盛研究院，此後共同參與組建江蘇省腫瘤新靶點及新藥發現集成原始創新聯合體，搭建起從靶點發現到臨床轉化的全鏈條創新集群。今天的簽約，標誌著雙方在既有基礎上進一步深化與拓展合作。對標《醫藥工業發展「十五五」規劃》提出的'2030年生物醫藥研發應用水平躋身世界前列'目標，以及'鼓勵藥企與國家臨床醫學研究中心深化合作'的導向，高水平醫院正由創新藥的使用終端，轉變為臨床問題的提出者、研究方案的定義者和真實價值的驗證者。我們期待與亞盛醫藥緊密合作，把臨床需求轉化為研究命題，把創新成果轉化為患者獲益，把合作優勢轉化為學科進步，共同為健康中國建設貢獻更多力量。」

楊大俊博士表示：「蘇州是中國生物醫藥的創新高地。蘇州大學擁有百年文脈，基礎醫學與生命科學學科實力突出，具備源頭創新的科研沃土；蘇大附一院作為血液系統疾病國家臨床醫學研究中心和中國血液學的重要發源地之一，吳德沛主任帶領團隊以一系列具有國際影響力的成果，持續引領中國血液腫瘤診療水平的提升。

亞盛2016年落戶蘇州，正是在這樣的創新生態中成長。公司始終堅持源頭創新，並於2020年與蘇大附一院血液科共建血液系統疾病國家臨床醫學研究中心亞盛研究院，聚焦血液腫瘤靶向藥物的轉化研究。六年過去，利生妥^®於2025年獲批上市，成為中國首個上市的國產原創Bcl-2抑制劑，重塑慢淋治療格局。

當前，國家正大力推動創新鏈與產業鏈深度融合，鼓勵企業牽頭的產學研用協同創新，打通從基礎研究到臨床應用的完整轉化路徑。很榮幸能與蘇州大學、蘇大附一院再次達成合作，一起打造協同創新的區域標桿，聚焦血液腫瘤領域，聯合開展前沿靶點挖掘、轉化醫學研究，共育生物醫藥複合型創新人才，搭建貫通高校基礎研究、臨床中心價值驗證、企業產業化轉化的可持續運轉的長效醫產協同創新平台。我們期待在三方同心協力之下，合力攻克血液腫瘤領域尚未解決的臨床難題，推動具有全球競爭力的中國原創新藥走向世界、惠及更多患者。」

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球範圍內進行知識產權佈局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物製藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關係。如需瞭解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2026年4月29日提交的20-F表格中截止2025年12月31日的年度報告中的「風險因素」和「關於前瞻性聲明的警示聲明」章節，2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

Expanding Next-Generation Network Capabilities and Accelerating the Innovative Convergence of Communication, Computing, and AI Laying a Solid Foundation for 6G Development in Hong Kong

HONG KONG, Oct. 17, 2026 /PRNewswire/ -- China Mobile Hong Kong Company Limited ("China Mobile Hong Kong") announced that it has taken the lead in realising a U6GHz network, successfully completing network testing and validation at its Mong Kok flagship store and advancing the exploration of Upper 6GHz band applications in mobile networks. Implementing China Mobile Group's strategy of "strengthening the network foundation and full-stack innovation", China Mobile Hong Kong aims to enhance network capabilities through new frequency band applications, drive collaborative innovation between terminals and the wider industry, and lay a robust foundation for Hong Kong's future 6G development.

Strategic Early Deployment of New Spectrum to Build Momentum for a 6G Future
U6GHz, or the Upper 6GHz band, can provide continuous wide bandwidth and is a crucial spectrum resource supporting 5G-A and future 6G evolution. On 29 November 2024, Hong Kong completed its 6/7GHz spectrum auction, becoming the first region globally to auction this frequency band for public mobile services. China Mobile Hong Kong successfully bid for 100MHz of continuous spectrum and has made appropriate forward-looking deployments, advancing network capability validation and terminal adaptation to accumulate experience for future 6G commercialisation.

Expanding Network Capacity to Enable Smoother Smart Applications
The newly added U6GHz spectrum can be utilised synergistically with existing frequency bands. Through various combinations with current spectrums, it can achieve download speeds of 3Gbps. The increased availability of spectrum helps enhance data transmission capabilities, accommodating more simultaneous user connections, improving the internet experience in highly congested areas, and supporting high-definition video and large-capacity data transmission.

As artificial intelligence becomes increasingly integrated into production and daily life, the demand for data transmission from devices such as smart glasses and AI robots continues to rise. China Mobile Hong Kong will promote the synergistic development of U6GHz and intelligent computing services, enhance connectivity between terminals and intelligent computing platforms, and explore AI image analysis, immersive interactions, and industrial applications. This will allow smart services to better integrate into everyday life and corporate operations.

Aligning with Mainland China and Hong Kong Blueprints to Consolidate the Foundation of Digital-Intelligent Development
China Mobile Hong Kong will actively align with the Nation's "15th Five-Year Plan" and Hong Kong's first Five-Year Plan. Focusing on "AI+", computing infrastructure, and new industrialisation, the company will enhance communication and smart services through network upgrades to assist Hong Kong in building an international innovation and technology centre. Concurrently, China Mobile Hong Kong will collaborate with industry partners to accelerate the research, development, and testing of U6GHz products. By expanding hotspot coverage according to demand, it aims to drive the maturity of the industrial ecosystem and accelerate Hong Kong's 6G development. Looking ahead, China Mobile Hong Kong will continue to leverage its strengths as a central state-owned enterprise, providing high-quality digital infrastructure to serve Hong Kong and the Guangdong-Hong Kong-Macao Greater Bay Area, thereby fully contributing to the building of a cyber superpower and a digital China.

About China Mobile Hong Kong Limited
China Mobile Hong Kong Company Limited ("China Mobile Hong Kong") is the wholly-owned subsidiary of China Mobile Limited (HKEx: 941), which is listed on the Fortune Global 500. China Mobile Hong Kong was incepted in January 1997 and was the first mobile network operator to launch PCS services in Hong Kong.

As the world's leading mobile network brand with the largest customer base*, The Company offers innovative and comprehensive 5G communications services, including voice, data, IDD and international roaming. The Company is committed to the development of 5G with new technologies such as artificial intelligence, internet of things, cloud computing and big data, integrating 5G applications in different industries, promoting the construction and development of smart city groups in Greater Bay Area.

* China Mobile (Hong Kong) Limited is a wholly-owned subsidiary of China Mobile Limited. As of 31 December 2025, China Mobile Limited had the largest number of mobile network subscribers in the world.

拓展新一代網絡能力 加速通算智融合創新
夯實香港6G發展基礎

香港2026年10月17日 /美通社/ -- 中國移動香港有限公司（下稱「中國移動香港」）宣佈，率先實現U6GHz網絡，於旺角旗艦店完成網絡測試及驗證，推進Upper 6GHz頻段在流動網絡的應用探索。落實中國移動集團「網絡強基、全棧創新」戰略，以新頻段應用提升網絡能力，帶動終端與產業協同創新，為香港未來6G發展奠定基礎。

提前佈局新頻譜 蓄力6G未來
U6GHz即Upper 6GHz頻段，可提供連續大頻寬，是支援5G-A及未來6G演進的重要頻譜資源。香港於2024年11月29日完成6/7GHz頻譜拍賣，成為全球首個拍賣該頻帶供公共流動服務使用的地區。中國移動香港投得100MHz連續頻譜，並適度超前部署，推進網絡能力驗證與終端適配，為未來6G商用積累經驗。

擴充網絡容量 讓智慧應用更暢順
新增U6GHz頻譜可與現有頻段協同使用，與現有頻譜通過頻譜聚合技術可實現3Gbps以上的下載速率。更多可用頻譜有助提升數據傳輸能力，容納更多用戶同時連接，改善繁忙區域的上網體驗，支援高清影像及大容量數據傳輸。

隨著人工智慧融入生產生活，智慧眼鏡、AI機械人等設備對數據傳輸的需求持續增加。中國移動香港將推動U6GHz與智算服務協同發展，提升終端與智算平臺的連接能力，探索AI影像分析、沉浸式互動及工業應用，讓智慧服務更好融入日常生活與企業營運。

對接國家與香港規劃 夯實數智發展底座
中國移動香港將積極配合國家「十五五」及香港首個五年規劃，聚焦「人工智慧＋」、算力基建與新型工業化，透過網絡升級完善通訊及智能服務，助力香港建設國際創科中心。同時，公司將聯同業界夥伴加快U6GHz產品研發與測試，並按需求擴展熱點覆蓋，推動產業生態成熟以加速香港6G發展。未來，中國移動香港會繼續發揮央企優勢，以高質量的數字基建服務香港與粵港澳大灣區，全面為建設網絡強國與數字中國貢獻力量。

關於中國移動香港有限公司 
中國移動香港有限公司（簡稱「中國移動香港」）隸屬中國移動有限公司（簡稱「中國移動」），《財富》雜誌「全球500強」企業，香港聯交所股份代號：941；於1997年1月正式提供服務，成為全港首個PCS流動網絡商。

作為全球最多客戶流動網絡品牌*，公司為客戶提供創新及多元化的5G通訊服務，包括話音、數據、IDD及國際漫遊等，並一直致力發展5G與人工智慧、物聯網、雲端計算、大數據等新技術結合，幫助各行各業實現5G的應用，推動大灣區智慧城市群建設與發展。

*中國移動香港有限公司為中國移動有限公司全資附屬公司。截至2025年12月31日，中國移動有限公司在全球擁有最多流動網絡客戶。